Test Catalog

Test ID: CD25    
CD25 Immunostain, Technical Component Only

Useful For Suggests clinical disorders or settings where the test may be helpful

Classification of lymphomas

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

CD25 is the receptor for IL2 and is expressed on activated T cells, B cells, and macrophages. It will stain only scattered cells in normal tonsil. CD25 is expressed in certain types of B-cell lymphoma (hairy cell leukemia) and T-cell lymphoma (adult T-cell lymphoma/leukemia [ATLL]). An anti-CD25 therapy can be used in patients who have lymphomas that express CD25.

Interpretation Provides information to assist in interpretation of the test results

This test does not include pathologist interpretation; only technical performance of the stain. If interpretation is required order PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case.


The positive and negative controls are verified as showing appropriate immunoreactivity and documentation is retained at Mayo Clinic Rochester. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request. Contact 855-516-8404.


Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen-dependent. Best practice is for paraffin sections to be cut within 6 weeks.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Kageyama Y, Miwa H, Arakawa R, et al: Expression of CD25 fluctuates in the leukemia-initiating cell population of CD25-positive AML. PLoS One. 2018;13(12):e0209295. doi:10.1371/journal.pone.0209295

2. deLeeuw RJ, Kroeger DR, Kost SE, Chang PP, Webb JR, Nelson BH: CD25 identifies a subset of CD4+FoxP3- TIL that are exhausted yet prognostically favorable in human ovarian cancer. Cancer Immunol Res. 2015 Mar;3(3):245-253. doi:10.1158/2326-6066.CIR-14-0146

3. Zhang W, Pan Y, Gou P, et al: Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model. Oncol Rep. 2018 Jan;39(1):280-288. doi:10.3892/or.2017.6094

4. Liu Y, Zhang H, Wang Z, Wu P, Gong W: 5-Hydroxytryptamine1a receptors on tumour cells induce immune evasion in lung adenocarcinoma patients with depression via autophagy/pSTAT3. Eur J Cancer. 2019 Jun;114:8-24. doi:10.1016/j.ejca.2019.03.017